BR112022019571A2 - Método para editar um ácido ribonucleico alvo, domínio dyw, proteína dyw, composição para editar ácido ribonucleico em uma célula eucariótica, ácido nucleico, vetor, e, célula - Google Patents

Método para editar um ácido ribonucleico alvo, domínio dyw, proteína dyw, composição para editar ácido ribonucleico em uma célula eucariótica, ácido nucleico, vetor, e, célula

Info

Publication number
BR112022019571A2
BR112022019571A2 BR112022019571A BR112022019571A BR112022019571A2 BR 112022019571 A2 BR112022019571 A2 BR 112022019571A2 BR 112022019571 A BR112022019571 A BR 112022019571A BR 112022019571 A BR112022019571 A BR 112022019571A BR 112022019571 A2 BR112022019571 A2 BR 112022019571A2
Authority
BR
Brazil
Prior art keywords
dyw
editing
target
ribonucleic acid
cell
Prior art date
Application number
BR112022019571A
Other languages
English (en)
Inventor
Ichinose Mizuho
gutmann Bernard
Yagi Yusuke
Akaiwa Yumi
Shimajiri Yasuka
Nakamura Takahiro
Original Assignee
Editforce Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Editforce Inc filed Critical Editforce Inc
Publication of BR112022019571A2 publication Critical patent/BR112022019571A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Botany (AREA)
  • Medicinal Chemistry (AREA)
  • Mycology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

MÉTODO PARA EDITAR UM ÁCIDO RIBONUCLEICO ALVO, DOMÍNIO DYW, PROTEÍNA DYW, COMPOSIÇÃO PARA EDITAR ÁCIDO RIBONUCLEICO EM UMA CÉLULA EUCARIÓTICA, ÁCIDO NUCLEICO, VETOR, E, CÉLULA. É provido um método para converter um alvo de edição C contido em um RNA alvo em U ou um alvo de edição U no mesmo em C. Um método para editar um RNA alvo, o dito método compreendendo aplicar, ao RNA alvo, uma proteína DYW artificial que contém um domínio DYW compreendendo um dos seguintes polipeptídeos a, b, c e bc: a. um polipeptídeo que tem xa1PGxa2SWIExa3-xa16HP ... HxaaE ... Cxa17xa18CH ... DYW, tem pelo menos 40% de identidade de sequência com a sequência de SEQ ID NO: 1, e tem uma atividade de edição C-para-U/U-para-C; b. um polipeptídeo que tem xb1PGxb2SWWTDxb3-xb16HP ... HxbbE ... Cxb17xb18CH ... DYW, tem pelo menos 40% de identidade de sequência com a sequência de SEQ ID NO: 2, e tem uma atividade de edição C-para-U/U-para-C; c. um polipeptídeo que tem KPAxc1Axc2IExc3 ... HxccE ... Cxc4xc5CH ... xc6xc7xc8, tem pelo menos 40% de identidade de sequência com a sequência de SEQ ID NO: 3, e tem uma atividade de edição C-para-U/U-para-C, e bc, um polipeptídeo que tem xb1PGxb2SWWTDxb3-xb16HP ... HxccE ... Cxc4xc5CH ... Dxbc1xbc2, tem pelo menos 40% de identidade de sequência com a sequência 90 de SEQ ID NO: 2, e tem uma atividade de edição C-para-U/U-para-C (nas sequências, x representa um aminoácido arbitrário e ... representa um fragmento de polipeptídeo arbitrário).
BR112022019571A 2020-03-31 2021-03-31 Método para editar um ácido ribonucleico alvo, domínio dyw, proteína dyw, composição para editar ácido ribonucleico em uma célula eucariótica, ácido nucleico, vetor, e, célula BR112022019571A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2020065065 2020-03-31
PCT/JP2021/014096 WO2021201198A1 (ja) 2020-03-31 2021-03-31 標的ｒｎａを編集する方法

Publications (1)

Publication Number Publication Date
BR112022019571A2 true BR112022019571A2 (pt) 2022-12-06

Family

ID=77930108

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022019571A BR112022019571A2 (pt) 2020-03-31 2021-03-31 Método para editar um ácido ribonucleico alvo, domínio dyw, proteína dyw, composição para editar ácido ribonucleico em uma célula eucariótica, ácido nucleico, vetor, e, célula

Country Status (11)

Country Link
US (1) US20230125942A1 (pt)
EP (1) EP4130274A4 (pt)
JP (1) JPWO2021201198A1 (pt)
KR (1) KR20220165747A (pt)
CN (1) CN115698296A (pt)
AU (1) AU2021248204A1 (pt)
BR (1) BR112022019571A2 (pt)
CA (1) CA3179365A1 (pt)
IL (1) IL296955A (pt)
TW (1) TW202204382A (pt)
WO (1) WO2021201198A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4331619A1 (en) * 2021-04-30 2024-03-06 Editforce, Inc. Therapeutic drug for myotonic dystrophy type 1
WO2023120658A1 (ja) * 2021-12-24 2023-06-29 国立大学法人北陸先端科学技術大学院大学 酵素、複合体、組換えベクター、遺伝性疾患治療薬及びポリヌクレオチド
CN117384884B (zh) * 2023-11-30 2024-03-08 辉大(上海)生物科技有限公司 IscB多肽及其用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2784157T (pt) 2011-10-21 2019-10-29 Univ Kyushu Nat Univ Corp Método para conceber proteínas de ligação a rna usando o motivo ppr e sua utilização
KR102390485B1 (ko) 2013-04-22 2022-04-22 고쿠리쓰다이가쿠호진 규슈다이가쿠 피피알 모티프를 가지는 디앤에이 결합 단백질을 포함하는 융합 단백질의 설계방법

Also Published As

Publication number Publication date
KR20220165747A (ko) 2022-12-15
EP4130274A4 (en) 2024-05-22
EP4130274A1 (en) 2023-02-08
CA3179365A1 (en) 2021-10-07
US20230125942A1 (en) 2023-04-27
CN115698296A (zh) 2023-02-03
TW202204382A (zh) 2022-02-01
AU2021248204A1 (en) 2022-11-10
JPWO2021201198A1 (pt) 2021-10-07
IL296955A (en) 2022-12-01
WO2021201198A1 (ja) 2021-10-07

Similar Documents

Publication Publication Date Title
BR112022019571A2 (pt) Método para editar um ácido ribonucleico alvo, domínio dyw, proteína dyw, composição para editar ácido ribonucleico em uma célula eucariótica, ácido nucleico, vetor, e, célula
BR112022008415A2 (pt) Composições e métodos para substituição do dna codificado pelo rna dos alelos
BR112019011277A2 (pt) polinucleotídeo, sistema de expressão recombinante, vetor, polipeptídeo, célula recombinante, polipeptídeo de receptor imune sintético isolado ou heterodímero de polipeptídeo, célula efetora imune ou célula-tronco, população de células imunes ou efetoras, métodos de fabricação de uma célula efetora imune que expressa sir, de geração de uma população de células modificadas por rna, de fornecimento de imunidade antidoença e de tratamento ou prevenção de uma doença, composição, uso ou método, kit, e, sequência de aminoácidos.
BR112021006844A8 (pt) Métodos para editar um rna alvo e para tratar ou prevenir uma doença ou condição, rna editado ou uma célula hospedeira tendo um rna editado, rna que recruta desaminase, construção, biblioteca, composição, célula hospedeira, e, kit para editar um rna alvo .
Ryazanov et al. Regulation of protein synthesis at the elongation stage New insights into the control of gene expression in eukaryotes
BR112022021789A2 (pt) Bibliotecas de ácido nucléico variantes para coronavírus
BR112022011235A2 (pt) Bibliotecas de variantes de ácido nucleico para receptores de adenosina
BR112019002238A2 (pt) polipeptídeo e célula manipulados, e, método de fermentação.
BR112021012665A2 (pt) Polipeptídeos úteis para edição de genes e métodos de uso
Podust et al. Replication factor C disengages from proliferating cell nuclear antigen (PCNA) upon sliding clamp formation, and PCNA itself tethers DNA polymerase δ to DNA
Lewis et al. The amino acid sequence of rabbit cardiac tropomyosin.
BR9708209A (pt) Polipeptídeo isolado tendo atividade fitase sequência de ácido nucleico isolada construção de ácido nucleico vetor de expressão recombinante célula hospedeira recombinante processo para produzir o polipeptídeo composição de alimento ou ração processo para reduzir os níveis de fitato em estrume de animais processo para liquefazer um amido e uso de um polipeptídeo
NO177433C (no) DNA-vektor for ekspresjon av desulfatohirudin i gjær eller E.coli samt fremgangsmåte for fremstilling av desulfatohirudin og salter derav
SG141233A1 (en) Control of gene expression
WO2004031346A3 (en) Methods and compositions concerning designed highly-specific nucleic acid binding proteins
BR0107703A (pt) Flavivìrus recombinantes e processos para uso dos mesmos
Xiao et al. Phosphorylation of HMG‐I by Protein Kinase C Attenuates Its Binding Affinity to the Promoter Regions of Protein Kinase C γ and Neurogranin/RC3 Genes
BR112022002695A2 (pt) Nucleases guiadas por rna, fragmentos ativos e variantes das mesmas e métodos de uso
BR112022014272A2 (pt) Fator de crescimento derivado de mieloide para uso no tratamento ou prevenção de fibrose, hipertrofia ou insuficiência cardíaca
Schneider et al. Posttranslational modifications of trichomonad tubulins; identification of multiple glutamylation sites
ATE294856T1 (de) Lunasin peptide
Mazina et al. Nuclear receptors EcR, Usp, E75, DHR3, and ERR regulate transcription of ecdysone cascade genes
BR112017022076A2 (pt) fusões de mesotelina-variante iii de receptor de fator de crescimento epidérmico e métodos de uso das mesmas
BR112018073674A2 (pt) polipeptídeo glicosilado, proteína glicosilada, uso de um polipeptídeo glicosilado, composição, polinucleotídeo isolado, vetor, e célula hospedeira
BR9712587A (pt) ‡cido nucléico, molécula de ácido nucléico, sonda, vetor de expressão recombinante, célula, processos para produzir um polipeptìdeo de h. pylori e para detectar a presença de um ácido nucléico de helicobacter pylori em uma amostra, polipeptìdeo de h. pylori isolado, polipeptìdeos de envelope de célula, celular e secretado de h. pylori ou seus fragmentos, proteìna de fusão, formulação de vacina para a profilaxia ou tratamento de uma infecção por h. pylori, e, processos para tratar ou reduzir um risco de infecção por h. pylori em um sujeito e para produzir uma formulação de vacina.